Michael Clayman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BURLINGTON, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference. The virtual fireside chat is scheduled to begin at 3:50 p.m. ET on Tuesday, June 8, 2021. To access the live webcast and subsequent archived recording of the presentation, please visit the Flexion websit

Share: BURLINGTON, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the RBC Capital Markets 2021 Virtual Global Healthcare Conference. The virtual fireside chat is scheduled to begin at 1:55 p.m. ET on Wednesday, May 19, 2021. To access the live webcast and subsequent archived recording of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.com. About Flexion Therapeutics Flexion Therapeutics...

Operator Good afternoon, ladies and gentlemen. And welcome to the Flexion Therapeutics First Quarter 2021 Financial Results Conference Call. [Operator Instructions] We will be facilitating a question-and-answer session at the end of today's call. [Operator Instructions] I'll now turn the call over to Scott Young, Flexion's Vice President of Corporate Communications and Investor Relations. Scott Young -- Vice President of Corporate Communications & Investor Relations Good afternoon. A short while ago, we issued a press release announcing our Q1 2021 financial results. In addition, today, we a...

Flexion Therapeutics Inc (FLXN) Q1 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. Flexion Therapeutics Inc (NASDAQ: FLXN) Popular Searches Operator Good afternoon, ladies and gentlemen, and welcome to the Flexion Therapeutics Business Update Call. [Operator Instructions] I will now turn the call over to Scott Young, Flexion's Vice President of Corporate Communications and Investor Relations.SPONSORED: 10 stocks we like better than Flexion Therapeutics When investing geniuses David and Tom Gardner have a s...

Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2020 Results Fourth-quarter 2020 ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales estimated to be approximately $26.3 million Full-year 2020 net sales estimated to be approximately $85.5 million Company names Adam Muzikant, Ph.D., Chief Business Officer BURLINGTON, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) — Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary and unaudited net sales for the fourth quarter and full year ended December 31, 2020. “We are v...